@conference{c7ad6e28df90485d95ea4e6398c292d9,
title = "Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).",
author = "Ahluwalia, \{Manmeet Singh\} and Yasmeen Rauf and Hong Li and Wen, \{Patrick Y.\} and Peereboom, \{David M.\} and Reardon, \{David A.\}",
note = "2015 Background: Trials with anti-PD1 in rGBM have shown limited efficacy. VEGF is highly up regulated proangiogenic growth factor in GBM contributing to tumor-associated immunosuppression. Preclinical data suggests a potential dose effect of anti-VEGF therapy on immunomodulation. Hence, a combination of anti-PD1 and anti-VEGF may be a promising approach in rGBM.; Journal of Clinical Oncology ; Conference date: 02-06-2023",
year = "2021",
month = may,
day = "20",
doi = "10.1200/JCO.2021.39.15\_SUPPL.2015",
language = "American English",
}